"Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents--their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. The previous edition was one of "Doody's Core Titles 2009." This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised"--Provided by publisher. Clinical strategies for cancer treatment: the role of drugs -- Target identification and drug discovery -- Clinical drug development and marketing approval -- Principles of pharmacokinetics -- Delivering anticancer drugs to brain tumors -- Pharmacogenetics -- Physical barriers to drug delivery -- Antifolates -- 5-fluoropyrimidines -- Cytidine analogues -- Purine antimetabolites -- Hydroxyurea -- Antimitotic drugs -- Alkylating agents -- Platinum analogues -- Bleomycin and other antitumor antibiotics -- Topoisomerase I-targeting drugs -- Topoisomerase II inhibitors: anthracyclines -- Topoisomerase II inhibitors: the epipodophyllotoxins -- Asparaginase -- Proteasome inhibitors -- Histone deacetylase inhibitors in oncology -- Differentiating agents -- Arsenic trioxide -- Antibodies -- Inhibitors of tumor angiogenesis -- Epidermal growth factor receptor inhibitors -- HER2 inhibitors -- Molecular targeted drugs -- Signaling inhibitors: IGFR, PI3K pathway, embryonic signaling inhibitors, and mitotic kinase inhibitors -- Cytokine therapy for cancer -- Cancer vaccines -- Adoptive cellular therapies -- Thalidomide and its analogs in the treatment of hematologic malignancies, including multiple myeloma, and solid tumors -- Hormonal therapy of breast cancer -- Hormone therapy for prostate cancer -- Drug therapy of pain in cancer patients -- Hematopoietic growth factors -- Antinausea medications -- Bisphosphonates and other bone-targeted therapies -- Intravenous access and catheter management -- Late effects of cancer chemotherapy -- Infertility after cancer chemotherapy.